{"entity":{"id":"ql1706","kind":"drug","name":"QL1706","aka":["Iparomlimab and Tuvonralimab，PSB205"],"tldr":"QL1706 is an experimental small-molecule drug from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer and colorectal cancer, with its target not yet stated publicly.","summary":"QL1706 (PSB205) is a small-molecule drug developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05487391 (A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection), NCT06686576 (A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer) and NCT05690945 (A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer), in non-small-cell lung cancer and colorectal cancer. The largest, NCT05487391, plans to enrol 632 participants with primary completion expected 2027-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of QL1706","url":"https://clinicaltrials.gov/search?intr=PSB205"},{"label":"Sponsor page","url":"https://www.qilu-pharma.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05487391","nct06686576","nct05690945","nct07256782"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PSB205","modality":"bifunctional antibody mixture (iparomlimab and tuvonralimab; INN stem -mab)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ql1706/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"trial":[{"id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/"},{"id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/"},{"id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/"},{"id":"nct07256782","kind":"trial","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","route":"/trials/nct07256782/"},{"id":"nct07353268","kind":"trial","name":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil","route":"/trials/nct07353268/"},{"id":"nct07649473","kind":"trial","name":"QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","route":"/trials/nct07649473/"},{"id":"nct07025239","kind":"trial","name":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","route":"/trials/nct07025239/"},{"id":"nct07009145","kind":"trial","name":"QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC","route":"/trials/nct07009145/"},{"id":"nct07156682","kind":"trial","name":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","route":"/trials/nct07156682/"},{"id":"nct06787183","kind":"trial","name":"SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases","route":"/trials/nct06787183/"}]}}